Novavax, Inc (NVAX)
followers
·
Follow
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Stanley C. Erck
Employees:
1990
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD, 20878
240-268-2000
Date | Ratio |
---|---|
2019-05-10 | 1:20 |
Novavax, Inc. focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial. NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate, is in Phase 3 clinical trial. ResVax is a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate.
All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
---|